NASDAQ: SNSE - Sensei Biotherapeutics, Inc.

Rentabilität für sechs Monate: -20.96%
Sektor: Healthcare

Aktionsplan Sensei Biotherapeutics, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors.

weitere details
It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

EBITDA -0.0124
EV/EBITDA -1.28
IPO date 2021-02-04
ISIN US81728A1088
Industry Biotechnology
P/BV 1
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.senseibio.com
Цена ао 1.04
Число акций ао 0.02795 млрд
Preisänderung pro Tag: +3.92% (0.4792)
Preisänderung pro Woche: +10.69% (0.4499)
Preisänderung pro Monat: -10.35% (0.5555)
Preisänderung über 3 Monate: -10.35% (0.5555)
Preisänderung über sechs Monate: -20.96% (0.6301)
Preisänderung pro Jahr: -28.03% (0.692)
Preisänderung über 3 Jahre: -91.31% (5.73)
Preisänderung über 5 Jahre: 0% (0.498)
Preisänderung über 10 Jahre: 0% (0.498)
Preisänderung seit Jahresbeginn: +9.67% (0.4541)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 0.2886 10
P/E 0 0
EV/EBITDA -0.3268 0
Gesamt: 3.75

Effizienz

Name Bedeutung Grad
ROA, % -45.85 0
ROE, % -52.55 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.1701 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 169.24 10
Rentabilität EPS, % -20.78 0
Gesamt: 5.6
Weitere Details

Institutionen Volumen Aktie, %
Newtyn Management, LLC 1572023 6.27
Vanguard Group Inc 573651 2.29
Renaissance Technologies, LLC 143508 0.57
Geode Capital Management, LLC 136318 0.54
Bridgeway Capital Management, Inc. 112900 0.45
Duquesne Family Office LLC 100000 0.4
Bank of America Corporation 90788 0.36
Millennium Management LLC 38295 0.15
Blackrock Inc. 34813 0.14
Northern Trust Corporation 26049 0.1



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. John K. Celebi M.B.A. President, CEO & Director 882.28k 1972 (53 Jahr)
Dr. Edward Van der Horst Ph.D. Chief Scientific Officer 630.81k 1974 (51 Jahr)
Ms. Lora Pike Vice President of Investor Relations & Communications N/A
Mr. Christopher W. Gerry J.D. Senior VP, General Counsel & Secretary N/A
Ms. Stephanie Krebs M.B.A., M.S. Chief Business Officer N/A 1978 (47 Jahre)
Dr. Aaron Weitzman FACP, M.D., Ph.D. Chief Medical Officer N/A
Mr. Josiah Craver Senior VP of Finance, Principal Financial Officer & Principal Accounting Officer

Adresse: United States, Rockville. MD, 1405 Research Boulevard - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.senseibio.com